Preventing Anthracycline-Associated Heart Failure: What Is the Role of Dexrazoxane?-Reference-Cited by-同舟云学术

Preventing Anthracycline-Associated Heart Failure: What Is the Role of Dexrazoxane?

Published:2024-04 Issue:2 Volume:6 Page:318-321
ISSN:2666-0873
Container-title:JACC: CardioOncology
language:en
Short-container-title:JACC: CardioOncology

Author:

Zheng Haoyi^ORCID,Zhan Huichun

Publisher

Elsevier BV

Reference11 articles.

1. Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy;Vaduganathan;J Am Coll Cardiol CardioOnc,2019

2. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended follow-up of a 2×2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol;Heck;Circulation,2021

3. Statins and left ventricular ejection fraction following doxorubicin treatment;Hundley;NEJM Evid,2022

4. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS);Lyon;Eur Heart J,2022

5. Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial;Neilan;JAMA,2023

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PCSK9 Inhibitors and Anthracyclines: The Future of Cardioprotection in Cardio-Oncology;Hearts;2024-09-03

2. Rationale and design of RESILIENCE: A prospective randomized clinical trial evaluating remote ischaemic conditioning for the prevention of anthracycline cardiotoxicity;European Journal of Heart Failure;2024-08-30

3. Trastuzumab-Induced Cardiotoxicity: When and How Much Should We Worry?;JCO Oncology Practice;2024-08